0 493

Cited 19 times in

Serum inflammatory profiles in pulmonary tuberculosis and their association with treatment response

DC Field Value Language
dc.contributor.author신성재-
dc.date.accessioned2017-10-26T07:57:54Z-
dc.date.available2017-10-26T07:57:54Z-
dc.date.issued2016-
dc.identifier.issn1874-3919-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/152750-
dc.description.abstractThe aim of this study was to evaluate serum cytokines and natural antimicrobial peptide profiles in pulmonary tuberculosis, and compare them with levels in controls without tuberculosis, to explore the associations between these biomarkers and response to antituberculosis treatment. Serum levels of 10 biomarkers were measured using a Luminex bead array platform. Tuberculosis biosignatures were identified from the discovery cohort (n=148) and were validated in the independent cohort (n=148). Association between biosignatures and clinical outcome was investigated with negative conversion in follow-up sputum culture after 2months of treatment. Serum concentrations of eotaxin, MIP-1α, sIL-2Rα, and lipocalin 2 were significantly different between pulmonary tuberculosis patients and controls (P<0.05). Serum concentrations of eotaxin and sIL-2Rα were higher in pulmonary tuberculosis patients than in controls, while those of MIP-1α and lipocalin 2 were lower (P<0.05). Eotaxin concentrations were significantly higher in good responders to treatment (P<0.05), indicating this immunomolecule may serve as a positive predictor for therapy response in pulmonary tuberculosis. The magnitude serum eotaxin, MIP-1α, sIL-2Rα, and lipocalin 2 are important indicators for pulmonary tuberculosis. These biomarkers alone or combinatorial detections have potential applicability in monitoring tuberculosis patients during antituberculosis treatment. SIGNIFICANCE: Cytokines and endogenous antimicrobial peptides represent an important part of immune system and the identification of a pattern of differentially expressed those biomarkers (a ""biosignature"") could help to differentiate tuberculosis infection from the non-infected state which might eventually assist case identification and accelerate access to treatment. In this direction, cytokine analysis including multiple serum biomarkers to evaluate biosignatures of pulmonary tuberculosis would provide basic knowledge to aid understanding of the pathophysiology of tuberculosis infection and for the development of future diagnostic methods, treatments, and monitoring for pulmonary tuberculosis.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfJOURNAL OF PROTEOMICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntitubercular Agents/therapeutic use*-
dc.subject.MESHBiomarkers/blood-
dc.subject.MESHChemokine CCL3/blood-
dc.subject.MESHCohort Studies-
dc.subject.MESHCytokines/blood*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHInterleukin-2/analogs & derivatives-
dc.subject.MESHInterleukin-2/blood-
dc.subject.MESHLipocalin-2/blood-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHSputum/chemistry-
dc.subject.MESHSputum/microbiology-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTuberculosis, Pulmonary/blood*-
dc.subject.MESHTuberculosis, Pulmonary/drug therapy-
dc.subject.MESHTuberculosis, Pulmonary/immunology-
dc.subject.MESHYoung Adult-
dc.titleSerum inflammatory profiles in pulmonary tuberculosis and their association with treatment response-
dc.typeArticle-
dc.publisher.locationNetherlands-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Microbiology-
dc.contributor.googleauthorRihwa Choi-
dc.contributor.googleauthorKyunga Kim-
dc.contributor.googleauthorMin-Ji Kim-
dc.contributor.googleauthorSu-Young Kim-
dc.contributor.googleauthorO Jung Kwon-
dc.contributor.googleauthorKyeongman Jeon-
dc.contributor.googleauthorHye Yun Park-
dc.contributor.googleauthorByeong-Ho Jeong-
dc.contributor.googleauthorSung Jae Shin-
dc.contributor.googleauthorWon-Jung Koh-
dc.contributor.googleauthorSoo-Youn Lee-
dc.identifier.doi10.1016/j.jprot.2016.06.016-
dc.contributor.localIdA02114-
dc.relation.journalcodeJ01721-
dc.identifier.eissn1876-7737-
dc.identifier.pmid27321581-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S187439191630255X?via%3Dihub-
dc.subject.keywordAntituberculosis treatment-
dc.subject.keywordBiomarker-
dc.subject.keywordImmunomolecule-
dc.subject.keywordSerum-
dc.subject.keywordTuberculosis-
dc.contributor.alternativeNameShin, Sung Jae-
dc.contributor.affiliatedAuthorShin, Sung Jae-
dc.citation.volume149-
dc.citation.startPage23-
dc.citation.endPage30-
dc.identifier.bibliographicCitationJOURNAL OF PROTEOMICS, Vol.149 : 23-30, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid39758-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.